Cargando…
Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran
Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. T...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139942/ https://www.ncbi.nlm.nih.gov/pubmed/27928477 |
_version_ | 1782472335414001664 |
---|---|
author | Seyedifar, Meysam Dorkoosh, Farid Abedin Hamidieh, Amir Ali Naderi, Majid Karami, Hossein Karimi, Mehran Fadaiyrayeny, Masoomeh Musavi, Masoumeh Safaei, Sanaz Ahmadian-Attari, Mohammad Mahdi Hadjibabaie, Molouk Cheraghali, Abdol Majid Akbari Sari, Ali |
author_facet | Seyedifar, Meysam Dorkoosh, Farid Abedin Hamidieh, Amir Ali Naderi, Majid Karami, Hossein Karimi, Mehran Fadaiyrayeny, Masoomeh Musavi, Masoumeh Safaei, Sanaz Ahmadian-Attari, Mohammad Mahdi Hadjibabaie, Molouk Cheraghali, Abdol Majid Akbari Sari, Ali |
author_sort | Seyedifar, Meysam |
collection | PubMed |
description | Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations. Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender. Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males. Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in. |
format | Online Article Text |
id | pubmed-5139942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-51399422016-12-07 Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran Seyedifar, Meysam Dorkoosh, Farid Abedin Hamidieh, Amir Ali Naderi, Majid Karami, Hossein Karimi, Mehran Fadaiyrayeny, Masoomeh Musavi, Masoumeh Safaei, Sanaz Ahmadian-Attari, Mohammad Mahdi Hadjibabaie, Molouk Cheraghali, Abdol Majid Akbari Sari, Ali Int J Hematol Oncol Stem Cell Res Original Article Background: Thalassemia is a chronic, inherited blood disorder, which in its most severe form, causes life-threatening anemia. Thalassemia patients not only engage with difficulties of blood transfusion and iron chelating therapy but also have some social challenges and health threatening factors. There are some reports on quality of life in thalassemia patients around the world from southeast of Asia to Italy in Europe and United States. In this study, we tried to evaluate and compare Health Related Quality of life (HRQoL) and the health utility in beta thalassemia major patients receiving different types of iron chelators and living in different socio-economical situations. Subjects and Methods: EQ-5D-3L accompanied by a Visual Analogue Scale (VAS) questionnaire was used. The respondents were patients with beta thalassemia major that were at least 12 years old selected from 3 provinces of Sistan-Blouchestan, Fars and Mazandaran. Comorbidities including heart complication, Diabetes Mellitus and Hepatitis and also types of iron chelators (oral, injection, combination of both) were also asked. Cross tab and ANOVA analysis conducted to evaluate each dimension score and health utility differences between provinces, iron chelation methods, comorbidities, age group and gender. Results: 528 patients answered the questionnaires. The health utility of patients that received oral iron chelator were 0.87 ± .01 for oral iron chelators versus 0.81 ± .01 for injection dosage form (p<0.05). Increase in age was accompanied by decrease in health utility. Females faced more usual activity problems, anxiety and depression. Heart problems were more prevalent in males. Conclusion: This study suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation treatment which they received, the gender they have, the comorbidities they suffer and socio-economical situations they live in. Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2016-10-01 /pmc/articles/PMC5139942/ /pubmed/27928477 Text en Copyright : © International Journal of Hematology-Oncology and Stem Cell Research & Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Seyedifar, Meysam Dorkoosh, Farid Abedin Hamidieh, Amir Ali Naderi, Majid Karami, Hossein Karimi, Mehran Fadaiyrayeny, Masoomeh Musavi, Masoumeh Safaei, Sanaz Ahmadian-Attari, Mohammad Mahdi Hadjibabaie, Molouk Cheraghali, Abdol Majid Akbari Sari, Ali Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
title | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
title_full | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
title_fullStr | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
title_full_unstemmed | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
title_short | Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran |
title_sort | health-related quality of life and health utility values in beta thalassemia major patients receiving different types of iron chelators in iran |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139942/ https://www.ncbi.nlm.nih.gov/pubmed/27928477 |
work_keys_str_mv | AT seyedifarmeysam healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT dorkooshfaridabedin healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT hamidiehamirali healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT naderimajid healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT karamihossein healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT karimimehran healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT fadaiyrayenymasoomeh healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT musavimasoumeh healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT safaeisanaz healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT ahmadianattarimohammadmahdi healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT hadjibabaiemolouk healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT cheraghaliabdolmajid healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran AT akbarisariali healthrelatedqualityoflifeandhealthutilityvaluesinbetathalassemiamajorpatientsreceivingdifferenttypesofironchelatorsiniran |